[1
]
Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Jianxing He, The First Affiliated
Hospital of Guangzhou Medical University, Guangdong; Xin Wang, Eli Lilly, Shanghai,
China; Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka; Kazuhiko Nakagawa, Kinki
University School of Medicine, Osaka; Sotaro Enatsu, Eli Lilly Japan, Kobe, Japan;
Pan-Chyr Yang and James Chih-Hsin Yang, National Taiwan University Hospital; James
Chih-Hsin Yang, National Taiwan University Cancer Center, Taipei, Taiwan; Jin Hyoung
Kang, The Catholic University of Korea, Seoul; Joo-Hang Kim, CHA Bundang Medical Center,
CHA University, Gyeonggi-do, Korea; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India;
and Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina.
[2
]
Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Jianxing He, The First Affiliated
Hospital of Guangzhou Medical University, Guangdong; Xin Wang, Eli Lilly, Shanghai,
China; Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka; Kazuhiko Nakagawa, Kinki
University School of Medicine, Osaka; Sotaro Enatsu, Eli Lilly Japan, Kobe, Japan;
Pan-Chyr Yang and James Chih-Hsin Yang, National Taiwan University Hospital; James
Chih-Hsin Yang, National Taiwan University Cancer Center, Taipei, Taiwan; Jin Hyoung
Kang, The Catholic University of Korea, Seoul; Joo-Hang Kim, CHA Bundang Medical Center,
CHA University, Gyeonggi-do, Korea; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India;
and Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina. chihyang@ntu.edu.tw.